NASDAQ:NEO - NeoGenomics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $40.95
  • Forecasted Upside: -9.51 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 1 Strong Buy Ratings
$45.26
▼ -0.41 (-0.90%)
1 month | 3 months | 12 months
Get New NeoGenomics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NEO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NEO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$40.95
▼ -9.51% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for NeoGenomics in the last 3 months. The average price target is $40.95, with a high forecast of $50.00 and a low forecast of $14.50. The average price target represents a -9.51% upside from the last price of $45.26.
Buy
The current consensus among 10 polled investment analysts is to buy stock in NeoGenomics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/3/2019
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/1/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2019
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2020
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2020
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/26/2020
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/24/2020

Latest Recommendations

  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2020SVB LeerinkBoost Price TargetOutperform$47.00 ➝ $50.00High
i
10/28/2020Craig HallumBoost Price TargetBuy$42.00 ➝ $50.00Low
i
10/28/2020Raymond JamesBoost Price TargetOutperform$40.00 ➝ $48.00Medium
i
10/28/2020BenchmarkBoost Price TargetBuy$40.00 ➝ $48.00High
i
10/28/2020Needham & Company LLCBoost Price TargetAverage ➝ Buy$39.00 ➝ $46.00High
i
10/28/2020SVB LeerinkBoost Price TargetOutperform$45.00 ➝ $47.00High
i
10/26/2020CIBCUpgradeOutperformer$10.50 ➝ $14.50Medium
i
9/9/2020Morgan StanleyInitiated CoverageOverweight$46.00High
i
8/28/2020GuggenheimInitiated CoverageBuy$46.00Medium
i
7/29/2020Craig HallumBoost Price TargetIn-Line ➝ Buy$36.00 ➝ $42.00Low
i
Rating by Alexander Nowak at Craig Hallum
7/29/2020SVB LeerinkBoost Price TargetOutperform$35.00 ➝ $45.00Low
i
7/29/2020Raymond JamesBoost Price TargetOutperform$32.00 ➝ $40.00Medium
i
7/29/2020BenchmarkBoost Price TargetBuy$35.00 ➝ $40.00High
i
7/29/2020Needham & Company LLCBoost Price TargetBuy$33.00 ➝ $39.00High
i
6/25/2020Bank of AmericaInitiated CoverageBuy$34.00High
i
5/27/2020Needham & Company LLCReiterated RatingBuy$33.00High
i
5/15/2020CIBCDowngradeNeutral$11.00 ➝ $9.00Low
i
4/29/2020SVB LeerinkReiterated RatingBuy$33.00 ➝ $35.00High
i
4/29/2020Needham & Company LLCReiterated RatingBuy$33.00High
i
4/21/2020StephensInitiated CoverageOverweight$33.00High
i
3/17/2020Needham & Company LLCBoost Price TargetBuy$32.00 ➝ $33.00High
i
3/2/2020Craig HallumInitiated CoverageBuy$38.00Low
i
3/2/2020Raymond JamesBoost Price TargetOutperform$28.00 ➝ $32.00High
i
2/28/2020BenchmarkBoost Price TargetAccumulate ➝ Buy$27.00 ➝ $30.00Medium
i
2/28/2020Needham & Company LLCBoost Price TargetBuy$29.00 ➝ $32.00Medium
i
2/28/2020First AnalysisUpgradeOutperform ➝ Strong-Buy$35.00High
i
1/23/2020First AnalysisDowngradeStrong-Buy ➝ Outperform$29.00 ➝ $35.00Low
i
1/3/2020Needham & Company LLCInitiated CoverageBuy$14.00Low
i
Rating by Stephen Unger at Needham & Company LLC
10/30/2019Needham & Company LLCBoost Price TargetBuy$27.00 ➝ $29.00High
i
Rating by Stephen Unger at Needham & Company LLC
10/29/2019William BlairReiterated RatingOutperformLow
i
Rating by B. Weinstein at William Blair
7/31/2019SVB LeerinkSet Price TargetBuy$30.00Medium
i
Rating by Puneet Souda at SVB Leerink LLC
7/31/2019Needham & Company LLCSet Price TargetBuy$27.00Medium
i
Rating by Stephen Unger at Needham & Company LLC
7/31/2019BenchmarkSet Price TargetBuy$27.00Medium
i
Rating by Bruce Jackson at Benchmark Co.
7/31/2019Raymond JamesBoost Price TargetOutperform$23.00 ➝ $27.00Medium
i
5/1/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $24.00High
i
3/29/2019Needham & Company LLCBoost Price TargetBuy ➝ Buy$19.00 ➝ $22.00High
i
3/12/2019CIBCUpgradeNeutral ➝ Outperform$18.00 ➝ $15.00Medium
i
1/3/2019Needham & Company LLCInitiated CoverageBuy ➝ Buy$14.00High
i
12/4/2018Raymond JamesReiterated RatingBuy$24.00High
i
Rating by John Hsu at Raymond James
11/16/2018ScotiabankReiterated RatingBuy ➝ Average$24.00Low
i
11/1/2018BenchmarkSet Price TargetBuy$22.00Medium
i
Rating by Bruce Jackson at Benchmark Co.
10/31/2018Raymond JamesBoost Price TargetOutperform ➝ Buy$16.00 ➝ $21.00Low
i
Rating by John Hsu at Raymond James
10/31/2018Craig HallumBoost Price TargetBuy$17.00 ➝ $22.00Medium
i
9/18/2018First AnalysisSet Price TargetBuy$16.00High
i
Rating by Joseph Munda at First Analysis
8/21/2018SVB LeerinkInitiated CoverageOutperform$18.00High
i
Rating by P. Souda at SVB Leerink LLC
6/26/2018StephensReiterated RatingBuy$15.00Medium
i
6/21/2018BTIG ResearchReiterated RatingBuy$15.00High
i
5/2/2018First AnalysisDowngradeOverweight ➝ Equal Weight$11.00Medium
i
Rating by Joseph Munda at First Analysis
4/16/2018BTIG ResearchUpgradeNeutral ➝ OutperformHigh
i
3/13/2018Canaccord GenuityBoost Price Target$23.00 ➝ $24.00Medium
i
3/13/2018Royal Bank of CanadaBoost Price TargetOutperform$23.00 ➝ $24.00Medium
i
3/13/2018ScotiabankBoost Price TargetOutperform$22.00 ➝ $23.00Medium
i
1/3/2018Royal Bank of CanadaSet Price TargetOutperform$23.00Low
i
1/3/2018ScotiabankSet Price TargetOutperform$22.00Low
i
1/3/2018CIBCSet Price TargetNeutral$19.00Low
i
10/26/2017Janney Montgomery ScottReiterated RatingBuyN/A
i
9/11/2017BTIG ResearchDowngradeBuy ➝ NeutralHigh
i
8/24/2017GabelliInitiated CoverageBuy$9.00High
i
5/28/2017BTIG ResearchReiterated RatingBuy$11.00Low
i
5/27/2017Cantor FitzgeraldSet Price TargetBuy$11.00N/A
i
4/26/2017Cantor FitzgeraldReiterated RatingBuy$11.00High
i
3/22/2017Cantor FitzgeraldReiterated RatingOverweight$11.00Low
i
3/13/2017Cantor FitzgeraldSet Price TargetBuy$11.00Low
i
2/22/2017Cantor FitzgeraldSet Price TargetBuy$11.00N/A
i
12/25/2016Cantor FitzgeraldSet Price TargetBuy$11.00N/A
i
12/15/2016Cantor FitzgeraldInitiated CoverageOverweight$11.00N/A
i
11/16/2016Axiom SecuritiesReiterated RatingHold ➝ SellN/A
i
10/27/2016BTIG ResearchUpgradeNeutral ➝ Buy$10.00N/A
i
10/3/2016First AnalysisInitiated CoverageOverweight$11.00N/A
i
9/8/2016Raymond JamesInitiated CoverageOutperform$10.00N/A
i
7/27/2016BenchmarkBoost Price TargetBuy$10.00 ➝ $12.00N/A
i
7/27/2016BTIG ResearchDowngradeBuy ➝ NeutralN/A
i
7/9/2016Craig HallumReiterated RatingBuyN/A
i
7/8/2016BTIG ResearchReiterated RatingBuy$10.00N/A
i
5/11/2016Roth CapitalInitiated CoverageBuy$10.00N/A
i
Rating by C. Lewis at Roth Capital
4/28/2016BenchmarkBoost Price TargetBuy$8.00 ➝ $9.00N/A
i
3/11/2016BenchmarkInitiated CoverageBuy$8.00N/A
i
3/3/2016BTIG ResearchReiterated RatingBuy$9.00N/A
i
1/7/2016Janney Montgomery ScottInitiated CoverageBuy$11.00N/A
i
(Data available from 11/24/2015 forward)
NeoGenomics logo
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides morphologic analysis which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Read More

Today's Range

Now: $45.26
$44.23
$46.07

50 Day Range

MA: $41.35
$36.08
$44.77

52 Week Range

Now: $45.26
$20.47
$46.00

Volume

17,673 shs

Average Volume

882,213 shs

Market Capitalization

$5.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68